Key facts
- LuSeed’s last known valuation is $6.7M (Nov 2023).
- It has raised $9.6M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Creative Destruction Lab, Global Support Capital, GlenRock Israel, Gandyr Investments, SHAAR — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for LuSeed
- ·The full record, as it builds
Funding rounds
No funding rounds for LuSeed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LuSeed
Developer of a medical device for brain aneurysm treatment designed to provide a minimally invasive, single-implant intervention. The company offers a dual-layer braided mesh design, angle-agnostic deployment, and minimal protrusion into parent arteries, enabling neurointerventional physicians to treat aneurysm patients more safely and with reduced reliance on strong blood thinners, making it more suitable for ruptured cases.
- Sector
- Healthcare
- HQ
- Petach Tikva, Israel
- Founded
- 2017
- Employees
- 16
- Website
- luseed-vascular.com/
- Ownership
- Privately Held (backing)
LuSeed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LuSeed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LuSeed in its N-PORT filings yet. We sweep new filings monthly.